At the same time, consistently with the quite equivocal benefits of combining Notch inhibition with cisplatin for osteosarcoma treatment, knockdown of Notch1 in this tumor model reduced the cytotoxic effects of doxorubicin partially related to the upregulation of Notch1 and its target genes [514]. Here, NOTCH1 is linked to osteosarcoma.